Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros




Base de datos
Asunto de la revista
Intervalo de año de publicación
1.
Environ Pollut ; 232: 533-545, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29032907

RESUMEN

Exposure of wildlife to Active Pharmaceutical Ingredients (APIs) is likely to occur but studies of risk are limited. One exposure pathway that has received attention is trophic transfer of APIs in a water-fish-osprey food chain. Samples of water, fish plasma and osprey plasma were collected from Delaware River and Bay, and analyzed for 21 APIs. Only 2 of 21 analytes exceeded method detection limits in osprey plasma (acetaminophen and diclofenac) with plasma levels typically 2-3 orders of magnitude below human therapeutic concentrations (HTC). We built upon a screening level model used to predict osprey exposure to APIs in Chesapeake Bay and evaluated whether exposure levels could have been predicted in Delaware Bay had we just measured concentrations in water or fish. Use of surface water and BCFs did not predict API concentrations in fish well, likely due to fish movement patterns, and partitioning and bioaccumulation uncertainties associated with these ionizable chemicals. Input of highest measured API concentration in fish plasma combined with pharmacokinetic data accurately predicted that diclofenac and acetaminophen would be the APIs most likely detected in osprey plasma. For the majority of APIs modeled, levels were not predicted to exceed 1 ng/mL or method detection limits in osprey plasma. Based on the target analytes examined, there is little evidence that APIs represent a significant risk to ospreys nesting in Delaware Bay. If an API is present in fish orders of magnitude below HTC, sampling of fish-eating birds is unlikely to be necessary. However, several human pharmaceuticals accumulated in fish plasma within a recommended safety factor for HTC. It is now important to expand the scope of diet-based API exposure modeling to include alternative exposure pathways (e.g., uptake from landfills, dumps and wastewater treatment plants) and geographic locations (developing countries) where API contamination of the environment may represent greater risk.


Asunto(s)
Monitoreo del Ambiente , Falconiformes/metabolismo , Preparaciones Farmacéuticas/análisis , Contaminantes Químicos del Agua/análisis , Animales , Bahías , Delaware , Peces/metabolismo , Cadena Alimentaria , Preparaciones Farmacéuticas/metabolismo , Ríos/química , Contaminantes Químicos del Agua/metabolismo
2.
Ann Biomed Eng ; 40(1): 106-13, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21997390

RESUMEN

Mild traumatic brain injury in sports has become a significant public health concern which has not only received the general public's attention through multiple news media stories involving athletic concussions, but has also resulted in local, state, and national legislative efforts to improve recognition and management. The purpose of this article is to review the current literature for return to play (RTP) guidelines. State, regional, national, and professional legislation on sport-related concussion RTP management issues will be reviewed. This article will be helpful in developing a generalized systematic approach to concussion management and highlight specific RTP guidelines. The article will also touch upon specific contraindications to RTP, the role of neuropsychological testing in RTP, and other considerations and complications that affect an athlete's ability to return to competition. Finally, considerations for terminating an athlete's competitive season or ending a career after sustaining a concussion resulting in prolonged and protracted symptomatology or repeated concussions will be reviewed. PubMed and Google were searched using the key terms mentioned below. In addition, the author's library of concussion-related articles was reviewed for the relevant literature.


Asunto(s)
Traumatismos en Atletas/rehabilitación , Conmoción Encefálica/rehabilitación , Recuperación de la Función , Toma de Decisiones , Gobierno Federal , Política de Salud/legislación & jurisprudencia , Humanos , Pruebas Neuropsicológicas , Jubilación , Deportes/legislación & jurisprudencia , Gobierno Estatal , Universidades/legislación & jurisprudencia
3.
Environ Toxicol Chem ; 30(5): 1213-22, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21337606

RESUMEN

The acute oral toxicity of the anticoagulant rodenticide diphacinone was found to be over 20 times greater in American kestrels (Falco sparverius; median lethal dose 96.8 mg/kg body weight) compared with Northern bobwhite (Colinus virginianus) and mallards (Anas platyrhynchos). Modest evidence of internal bleeding was observed at necropsy, although histological examination of heart, liver, kidney, lung, intestine, and skeletal muscle revealed hemorrhage over a wide range of doses (35.1-675 mg/kg). Residue analysis suggests that the half-life of diphacinone in the liver of kestrels that survived was relatively short, with the majority of the dose cleared within 7 d of exposure. Several precise and sensitive clotting assays (prothrombin time, Russell's viper venom time, thrombin clotting time) were adapted for use in this species, and oral administration of diphacinone at 50 mg/kg increased prothrombin time and Russell's viper venom time at 48 and 96 h postdose compared with controls. Prolongation of in vitro clotting time reflects impaired coagulation complex activity, and generally corresponded with the onset of overt signs of toxicity and lethality. In view of the toxicity and risk evaluation data derived from American kestrels, the involvement of diphacinone in some raptor mortality events, and the paucity of threshold effects data following short-term dietary exposure for birds of prey, additional feeding trials with captive raptors are warranted to characterize more fully the risk of secondary poisoning.


Asunto(s)
Anticoagulantes/toxicidad , Falconiformes/metabolismo , Fenindiona/análogos & derivados , Rodenticidas/toxicidad , Animales , Coagulación Sanguínea/efectos de los fármacos , Colinus/metabolismo , Relación Dosis-Respuesta a Droga , Hígado/efectos de los fármacos , Hígado/patología , Pulmón/efectos de los fármacos , Pulmón/patología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Fenindiona/toxicidad , Bazo/efectos de los fármacos , Bazo/patología , Pruebas de Toxicidad Aguda
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA